Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Jury Finds in Favor of Takeda in Actos Lawsuit, Turning Down Plaintiff’s Claim
May 19, 2014
- Olmesartan Sales Exceed 300 Billion Yen in FY2013: Daiichi Sankyo
May 16, 2014
- Generic Makers See Softer Sales Growth in FY2013
May 16, 2014
- Merck Deal Marks a Stride towards Top 3 in Global Ophthalmic Space: Santen Veep
May 16, 2014
- Daiichi Sankyo Chair Shoda to Bow Out, Become Adviser
May 16, 2014
- Nichi-Iko to Assign over 70 Sales Reps Specializing in DPC Hospitals within 2014
May 16, 2014
- Otsuka Holdings’ Pharmaceutical Sales Top 1 Trillion Yen for First Time
May 15, 2014
- Hisamitsu Takes Aim at 190 Billion Yen Sales in FY2018
May 15, 2014
- Ono to Introduce Sales Reps Specializing in Oncology for Entry to Oncology Market in Japan
May 15, 2014
- Zeria Appoints New President for First Time in 32 Years
May 14, 2014
- Meiji Seika Pharma Pres. Matsuo to Helm Holding Firm
May 14, 2014
- Eisai Sales Up 4.7% Thanks to Humira, Halaven Growth
May 14, 2014
- Santen Acquires Merck’s Eye Drugs in Japan, Key Markets
May 14, 2014
- 4 Major Wholesalers’ Average Operating Margin Tops 1% Mark, Signaling Biz Recovery
May 13, 2014
- Astellas FY2013 Sales Up 16% on Rosy Revenues from Xtandi, Betanis
May 13, 2014
- March Ethical Drug Sales Zoom 13.8% on Pre-Tax Hike Demand: Crecon Report
May 13, 2014
- Astellas Pres. “Aware” of Rumored Marriage with Daiichi Sankyo, but Denies Any Merger at This Time
May 13, 2014
- Questionnaire Survey of Chronic Myeloid Leukemia Patients Finds 30 Unreported ADRs: Novartis
May 13, 2014
- Nippon Kayaku Predicts Remicade Biosimilar Sales of 1.1 Billion Yen for FY2014
May 13, 2014
- MTPC Plans to Reduce Costs by 10 Billion Yen by FY2016
May 12, 2014
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…